BACKGROUND: The goal of this study is to determine the efficacy and toxicity of weekly irinotecan as second-line chemotherapy in advanced gastric cancer after failure of cisplatin-based regimen. METHODS: Gastric cancer patients failing cisplatin-based chemotherapy received 125 mg/m(2) of irinotecan weekly for 4 weeks followed by 2-week rest, until disease progression. RESULTS: Thirty-seven patients were enrolled into this study. The objective response was documented in seven of 35 patients with measurable lesion (response rate 20%, 95% CI: 6.1-33.9). Eight patients (22.9%) had stable disease and overall tumor control rate was 42.9%. The disease remained stable in both of two patients without measurable disease. At a median follow-up duration of 15.8 months, median time to progression and overall survival were 2.6 months (95% CI: 2.4-2.8) and 5.2 months (95% CI: 3.6-6.7), respectively. Neutropenia and diarrhea were the main toxicities. Among 37 patients treated, grade 3/4 (G3/4) neutropenia occurred in 43.2/24.3% of patients, respectively, and was accompanied with fever in three patients. Non-hematologic toxicities consisted mainly of delayed diarrhea (G3/4, 18.9/0%) and nausea/vomiting (G3/4, 18.9/0%). These toxicities were manageable and there was no treatment-related death. CONCLUSIONS: This weekly schedule of irinotecan was modestly active against cisplatin-refractory gastric cancer and relatively well-tolerated with appropriate dose modification.
BACKGROUND: The goal of this study is to determine the efficacy and toxicity of weekly irinotecan as second-line chemotherapy in advanced gastric cancer after failure of cisplatin-based regimen. METHODS:Gastric cancerpatients failing cisplatin-based chemotherapy received 125 mg/m(2) of irinotecan weekly for 4 weeks followed by 2-week rest, until disease progression. RESULTS: Thirty-seven patients were enrolled into this study. The objective response was documented in seven of 35 patients with measurable lesion (response rate 20%, 95% CI: 6.1-33.9). Eight patients (22.9%) had stable disease and overall tumor control rate was 42.9%. The disease remained stable in both of two patients without measurable disease. At a median follow-up duration of 15.8 months, median time to progression and overall survival were 2.6 months (95% CI: 2.4-2.8) and 5.2 months (95% CI: 3.6-6.7), respectively. Neutropenia and diarrhea were the main toxicities. Among 37 patients treated, grade 3/4 (G3/4) neutropenia occurred in 43.2/24.3% of patients, respectively, and was accompanied with fever in three patients. Non-hematologic toxicities consisted mainly of delayed diarrhea (G3/4, 18.9/0%) and nausea/vomiting (G3/4, 18.9/0%). These toxicities were manageable and there was no treatment-related death. CONCLUSIONS: This weekly schedule of irinotecan was modestly active against cisplatin-refractory gastric cancer and relatively well-tolerated with appropriate dose modification.
Authors: Young Saing Kim; Junshik Hong; Sun Jin Sym; Se Hoon Park; Jinny Park; Eun Kyung Cho; Jae Hoon Lee; Dong Bok Shin Journal: Cancer Res Treat Date: 2010-03-31 Impact factor: 4.679
Authors: Harald Schmalenberg; Salah-Eddin Al-Batran; Claudia Pauligk; Thomas Zander; Alexander Reichart; Udo Lindig; Mathias Kleiß; Lothar Müller; Claus Bolling; Thomas Seufferlein; Peter Reichardt; Frank Kullmann; Henning Eschenburg; Alexander Schmittel; Matthias Egger; Andreas Block; Thorsten Oliver Goetze Journal: J Cancer Res Clin Oncol Date: 2017-12-28 Impact factor: 4.553
Authors: M Vickers; B Samson; B Colwell; C Cripps; D Jalink; S El-Sayed; E Chen; G Porter; R Goel; J Villeneuve; S Sundaresan; J Asselah; J Biagi; D Jonker; L Dawson; R Letourneau; M Rother; J Maroun; M Thirlwell; M Hussein; M Tehfe; N Perrin; N Michaud; N Hammad; P Champion; R Rajan; R Burkes; S Barrette; S Welch; N Yarom; T Asmis Journal: Curr Oncol Date: 2010-06 Impact factor: 3.677
Authors: Mehmet Ali Nahit Sendur; Nuriye Ozdemir; Tahsin Özatlı; Ozan Yazıcı; Sercan Aksoy; Ahmet Siyar Ekinci; Doğan Yazılıtaş; Yusuf Günaydın; Berna Oksuzoglu; Mustafa Benekli; Nurullah Zengin Journal: Med Oncol Date: 2014-08-07 Impact factor: 3.064